KYNBHIGH SIGNALOPERATIONAL10-K

KYNB has undergone a major corporate transformation, rebranding from FibroGen to Kyntra Bio while substantially reducing operating losses and restructuring its balance sheet.

The company appears to have completed a significant divestiture or restructuring that dramatically reduced its scale of operations while improving cash flow dynamics. The name change to Kyntra Bio and references to winding up the Cayman Subsidiary suggest a major corporate reorganization, potentially following the sale of international operations to AstraZeneca as referenced in the risk factors.

Comparing 2026-03-16 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

The financial profile shows a company that has meaningfully contracted in scale, with revenue declining substantially from $29.6M to $6.4M, while R&D expenses dropped proportionally from $95.7M to $23.5M. However, operating cash flow improved dramatically from -$138.0M to -$4.8M, and the balance sheet was substantially restructured with current liabilities falling from $133.3M to $29.2M and stockholders' equity deficit improving notably from -$225.6M to -$30.0M. The overall picture suggests a successful downsizing that has created a more sustainable cost structure despite the reduced revenue base.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+96.5%
-$138.0M→-$4.8M

Operating cash flow surged 96.5% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+86.7%
-$225.6M→-$30.0M

Equity base grew 86.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-85.7%
$266K→$38K

Capex reduced 85.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
-78.3%
$29.6M→$6.4M

Revenue declined 78.3% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
-78.1%
$133.3M→$29.2M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-75.4%
$95.7M→$23.5M

R&D spending cut 75.4% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
-71.1%
$398.2M→$115.1M

Liabilities reduced 71.1% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+69.5%
-$150.4M→-$45.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
-55.1%
$481K→$216K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Assets
Balance Sheet
-49.6%
$196.5M→$99.1M

Current assets declined 49.6% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-17
ADDED
2 RISK FACTOR SU MMARY The success of Kyntra Bio will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following: Risks Related to the Development and Commercialization of Our Product Candidates We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our PET (as defined below) imaging agent FG-3180).
The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.
and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
International Risks Within the next year, we may face costs from the wind-up of the Cayman Subsidiary (as defined below), and may not receive some of the AZ Holdbacks (as defined below) related to the sale of FibroGen International and its subsidiaries.
and China relations, as well as relations with other countries, and/or regulations may adversely impact our business.
+7 more — sign up free →
REMOVED
2 RISK FACTOR SU MMARY The success of FibroGen will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following: Risks Related to the Development and Commercialization of Our Product Candidates We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our positron emission tomography ( PET ) imaging agent FG-3180).
The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the United States, and we may encounter significant problems in securing and defending our intellectual property rights outside the United States.
We are subject to stringent and evolving United States and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
Risks Related to Our International Operations If we are unable to consummate the sale of FibroGen International to AstraZeneca Treasury Limited, the trading price of our common stock and our business may be harmed.
We have established operations in China and there are a number of risks associated with international operations could materially and adversely affect our business.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →